2-(trans-4-Methylcyclohexyl)ethanol | 76833-27-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(trans-4-Methylcyclohexyl)ethanol
• 英文别名: 2-(cis-4-Methylcyclohexyl)ethanol；trans-4-methylcyclohexyl-ethanol；cis-4-methylcyclohexyl-ethanol
• CAS: 76833-27-7
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: HIORXFCYDCJZPW-KYZUINATSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.23
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  2-(trans-4-Methylcyclohexyl)ethanol 在 吡啶 、 lithium aluminium tetrahydride 、 sodium azide 作用下， 生成 2-(cis-4-Methylcyclohexyl)ethylamine
  参考文献：
  名称：

  Conformational analysis. 40. Conformation of 1-methyl-1-phenylcyclohexane and conformational energies of the phenyl and vinyl groups

  摘要：

  DOI：

  10.1021/jo00322a056
• 作为产物：
  描述：

  (cis-4-methyl-cyclohexyl)-acetic acid 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以82%的产率得到2-(trans-4-Methylcyclohexyl)ethanol
  参考文献：
  名称：

  Conformational analysis. 40. Conformation of 1-methyl-1-phenylcyclohexane and conformational energies of the phenyl and vinyl groups

  摘要：

  DOI：

  10.1021/jo00322a056

文献信息

• [EN] 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS<br/>[FR] PURINES 2,6,7 SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE HDM2
  申请人：MERCK SHARP & DOHME

  公开号：WO2014123882A1

  公开（公告）日：2014-08-14

  The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供如上所述的2,6,7取代嘌呤或其药用可接受的盐。代表性化合物可用作HDM2蛋白的抑制剂。还披露了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS
  申请人：SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

  公开号：US20160096811A1

  公开（公告）日：2016-04-07

  Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D 3 receptor, 5-HT 1A receptor and 5-HT 2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.

  本发明涉及苯并异噻唑化合物及其在制备抗精神分裂症药物中的应用。本发明的苯并异噻唑化合物不仅具有与多巴胺D3受体、5-HT1A受体和5-HT2A受体的强亲和力，而且可以明显改善与阿泼吗啡模型和MK-801模型小鼠相关的精神分裂症症状，口服吸收良好，安全性高，副作用少，并具有作为新型抗神经症药物的开发价值。本发明是具有通式（I）结构的化合物，或其几何异构体、自由碱、盐、水合物或溶剂化物。
• 4-AMINO-5-OXO-7,8-DIHYDROPYRIMIDO[5,4-F][1,4]OXAZEPIN-6(5H)-YL PHENYL DERIVATIVES
  申请人：Aspnes Gary E.

  公开号：US20100204119A1

  公开（公告）日：2010-08-12

  The invention provides compounds of Formula (I), wherein R 1 , R 2a , R 2b , R 3 , m and A are as defined herein, as well as compositions thereof and methods for treating a disease, condition or disorder that is modulated by the inhibition of the diacylglycerol O-acyltransferase 1 (DGAT-1) enzyme by administering the compounds of the present invention and/or compositions thereof.

  本发明提供了式（I）的化合物，其中R1，R2a，R2b，R3，m和A如本文所定义，以及它们的组合物和通过给予本发明的化合物和/或组合物来抑制二酰甘油O-酰基转移酶1（DGAT-1）酶而治疗受DGAT-1调节的疾病，情况或紊乱的方法。
• 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2953470A1

  公开（公告）日：2015-12-16
• DEVICE CONTAINING A LIQUID-CRYSTALLINE MEDIUM
  申请人：Merck Patent GmbH

  公开号：EP2986689B1

  公开（公告）日：2017-04-19